X0306 4 2019-03-14 0 0000722830 IMMUNOMEDICS INC IMMU 0001752213 Fricker William C/O IMMUNOMEDICS, INC. 300 THE AMERICAN ROAD MORRIS PLAINS NJ 07950 0 1 0 0 PRINCIPAL ACCOUNTING OFFICER Stock Option (right to buy) 17.94 2019-03-14 4 A 0 8560 0 A 2026-03-14 Common Stock, par value $0.01 per share 8560 8560 D Stock Option (right to buy) 17.94 2019-03-14 4 A 0 4280 0 A 2026-03-14 Common Stock, par value $0.01 per share 4280 4280 D The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan (the "Plan"). The stock options vest 25% on the first anniversary of the date of grant, and in 6.25% in equal quarterly installments thereafter. The reporting person was granted stock options pursuant to the Plan. The stock options vest (i) 50% upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act, and (ii) 50% on the second anniversary of the date of grant. /s/ William Fricker 2019-03-18